晚期临床和回声心脏学结果与Magna Ease©心周大动脉生物假体
Amedeo Anselmi1,2, Marie Aymami1,2, Jacques Tomasi1,2
1Division of Thoracic and Cardiovascular Surgery, Pontchaillou University Hospital, Rennes, France.
概括
佩里蒙特MagnaEase生物假体显示了手术大动脉置换 (SAVR) 的长期良好结果. 免受结构的恶化和重新干预的情况在10年内仍然很高.
科学领域:
- 心血管外科心血管外科
- 生物假体门的使用方法
- 大动脉门的更换
背景情况:
- 接受大动脉置换手术 (SAVR) 的患者群体正在发生变化.
- 佩里蒙特MagnaEase生物假体是SAVR的一个相对较新的选择.
研究的目的:
- 评估Perimount Magna Ease生物假体在全新SAVR群体中的长期结果.
- 评估门相关事件,包括结构门恶化和患者假肢不匹配.
主要方法:
- 一个单一中心的队列研究,使用Magna Ease门 (2008-2014) 连续1016次SAVR.
- 预期数据收集与系统的临床和心声谱随访.
- 对门相关事件的分析:结构门恶化 (SVD),非结构门功能障碍和患者假肢不匹配 (PPM).
主要成果:
- 整体10年生存率为56.8%.
- 10年后从SVD中脱离的比例为96.5% (Kaplan-Meier),其中15次SVD重复干预.
- 中度和严重的PPM分别发生在26.8%和5.4%的患者中,但没有影响晚期死亡率.
结论:
- 佩里蒙特MagnaEase生物假体在SAVR患者中显示出有利的长期结果.
- 对于预期寿命超过10-12年的患者,建议继续进行随访.
相关概念视频
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
01:22Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...